Manuel Herminio Aguiar-Oliveira

Manuel Herminio Aguiar-Oliveira

Auto-generated profile, based on publicly available information

Manuel Herminio Aguiar-Oliveira

Division of Endocrinology, Health Sciences Graduate Program, Federal University of Sergipe, Aracaju, Brazil

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2018 in Endocrine Reviews
Verified
Journal Article
Closed access
PDF file
MAManuel H Aguiar-Oliveira
Manuel H Aguiar-Oliveira
ABAndrzej Bartke
Andrzej Bartke
The important role of GH in the control of mammalian longevity was first deduced from extended longevity of mice with genetic GH deficiency (GHD) or GH resistance. Mice with isolated GHD (IGHD) due to GHRH or GHRH receptor mutations, combined deficiency of GH, prolactin, and TSH, or global deletion of GH receptors live longer than do their normal siblings. They also exhibit multiple features of delayed and/or slower aging, accompanied by extension of healthspan. The unexpected, remarkable longevity benefit of severe endocrine defects in these animals presumably represents evolutionarily conserved trade-offs among aging, growth, maturation, fecundity, and the underlying anabolic processes. Importantly, the negative association of GH signaling with longevity extends to other mammalian species, apparently including humans. Data obtained in humans with IGHD type 1B, owing to a mutation of the GHRH receptor gene, in the Itabaianinha County, Brazil, provide a unique opportunity to study the impact of severe reduction in GH signaling on age-related characteristics, health, and functionality. Individuals with IGHD are characterized by proportional short stature, doll facies, high-pitched voices, and central obesity. They have delayed puberty but are fertile and generally healthy. Moreover, these IGHD individuals are partially protected from cancer and some of the common effects of aging and can attain extreme longevity, 103 years of age in one case. We think that low, but detectable, residual GH secretion combined with life-long reduction of circulating IGF-1 and with some tissue levels of IGF-1 and/or IGF-2 preserved may account for the normal longevity and apparent extension of healthspan in these individuals.

1 August 2017 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
MAManuel H Aguiar-Oliveira
Manuel H Aguiar-Oliveira
ASAnita H O Souza
Anita H O Souza
COCarla R P Oliveira
Carla R P Oliveira
VCViviane C Campos
Viviane C Campos
LOLuíz A Oliveira-Neto
Luíz A Oliveira-Neto
RSRoberto Salvatori
Roberto Salvatori
Twenty years ago, we described kindred of 105 individuals with isolated GH deficiency (IGHD) in Itabaianinha County, in northeast Brazil, carrying a homozygous mutation in the GH-releasing hormone receptor gene. These subjects exhibit markedly reduced GH responsiveness to stimulatory tests, and anterior pituitary hypoplasia. Serum concentrations of IGF-I, IGF binding protein type 3 and the acid-labile subunit are markedly reduced, with a lesser reduction of IGF-II. The most striking physical findings of these IGHD individuals are the proportionate short stature, doll facies, high-pitched voice and visceral obesity with reduced fat-free mass. There is neither microphallus, nor neonatal hypoglycemia. Puberty is delayed, menopause anticipated, but fertility is preserved in both genders. The reduction in bone sizes is not even, with mean standard deviation scores for height of −7.2, total maxillary length of −6.5, total facial height of −4.3 and cephalic perimeter of −2.7. In addition, the non-osseous growth is not uniform, preserving some organs, like pancreas, liver, kidney, brain and eyes, and compromising others such as thyroid, heart, uterus and spleen. These subjects present higher prevalence of dizziness, mild high-tones sensorineural hearing loss, reduction of vascular retinal branching points, increase of optic disk, genu valgum and increased systolic blood pressure. Biochemically, they have high low density lipoprotein cholesterol and C-reactive protein levels, but maintain increased insulin sensitivity, and do not show premature atherosclerosis. Finally, they have normal immune function, and normal longevity. This review details the findings and summarizes 20 years of clinical research carried out in this unique population.

16 September 2020 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
MAManuel H. Aguiar-Oliveira
Manuel H. Aguiar-Oliveira
RSRoberto Salvatori
Roberto Salvatori

1 July 2011 in The Angle Orthodontist
Verified
Journal Article
Closed access
LOLuiz Alves Oliveira-Neto
Luiz Alves Oliveira-Neto
MMMariade Fátima B. Melo
Mariade Fátima B. Melo
AFAlexandre A. Franco
Alexandre A. Franco
AOAlaíde H. A. Oliveira
Alaíde H. A. Oliveira
ASAnita H. O. Souza
Anita H. O. Souza
MAManuel H. Aguiar-Oliveira
Manuel H. Aguiar-Oliveira
Objective: To analyze cephalometric features in adults with isolated growth hormone (GH) deficiency (IGHD). Materials and Methods: Nine adult IGHD individuals (7 males and 2 females; mean age, 37.8 ± 13.8 years) underwent a cross-sectional cephalometric study, including 9 linear and 5 angular measurements. Posterior facial height/anterior facial height and lower-anterior facial height/anterior facial height ratios were calculated. To pool cephalometric measurements in both genders, results were normalized by standard deviation scores (SDS), using the population means from an atlas of the normal Brazilian population. Results: All linear measurements were reduced in IGHD subjects. Total maxillary length was the most reduced parameter (−6.5 ± 1.7), followed by a cluster of six measurements: posterior cranial base length (−4.9 ± 1.1), total mandibular length (−4.4 ± 0.7), total posterior facial height (−4.4 ± 1.1), total anterior facial height (−4.3 ± 0.9), mandibular corpus length (−4.2 ± 0.8), and anterior cranial base length (−4.1 ± 1.7). Less affected measurements were lower-anterior facial height (−2.7 ± 0.7) and mandibular ramus height (−2.5 ± 1.5). SDS angular measurements were in the normal range, except for increased gonial angle (+2.5 ± 1.1). Posterior facial height/anterior facial height and lower-anterior facial height/anterior facial height ratios were not different from those of the reference group. Conclusions: Congenital, untreated IGHD causes reduction of all linear measurements of craniofacial growth, particularly total maxillary length. Angular measurements and facial height ratios are less affected, suggesting that lGHD causes proportional blunting of craniofacial growth.

1 January 2026 in Physiology
Verified
Journal Article
Closed access
MAManuel H. Aguiar-Oliveira
Manuel H. Aguiar-Oliveira
MBMargaret C. S. Boguszewski
Margaret C. S. Boguszewski
DRDiego L. Rovaris
Diego L. Rovaris
Jose DonatoJose Donato
Jose Donato
Growth hormone (GH) is secreted by the anterior pituitary gland under the control of hypothalamic neuroendocrine neurons that express somatostatin or growth hormone-releasing hormone (GHRH). Ghrelin, originating primarily in the stomach, is also an important GH secretagogue. GH stimulates the hepatic secretion of insulin-like growth factor-1 (IGF-1) and the expression of IGF-1 in extrahepatic tissues, including the brain. Many regions of the brain express receptors for GH, IGF-1, and ghrelin. In recent decades, evidence from both human and animal studies has indicated that GH, IGF-1, and ghrelin regulate numerous brain functions. Alterations in the secretion or sensitivity to these hormones may represent risk factors for developing neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s) and neuropsychiatric conditions (such as depression, anxiety, posttraumatic stress disorder, schizophrenia, and bipolar disorder). Additionally, classical neurodevelopmental disorders such as autism spectrum and attention-deficit hyperactivity disorders may also be influenced by somatotropic hormones. This review aims to summarize and discuss the emerging role of GH and IGF-1 in influencing brain function and the predisposition to brain diseases and neuropsychiatric disorders.

12 June 2021 in Aging Cell
Verified
Journal Article
Open access
PDF file
TSTatiana D. Saccon
Tatiana D. Saccon
ASAugusto Schneider
Augusto Schneider
CMCindi G. Marinho
Cindi G. Marinho
ANAllancer D. C. Nunes
Allancer D. C. Nunes
SNSarah Noureddine
Sarah Noureddine
MMMichal M. Masternak
Michal M. Masternak
Reduced inflammation, increased insulin sensitivity, and protection against cancer are shared between humans and mice with GH/IGF1 deficiency. Beyond hormone levels, miRNAs are important regulators of metabolic changes associated with healthy aging. We hypothesized that GH deficiency in humans alters the abundance of circulating miRNAs and that a subset of those miRNAs may overlap with those found in GH‐deficient mice. In this study, subjects with untreated congenital isolated GH deficiency (IGHD; n = 23) and control subjects matched by age and sex (n = 23) were recruited and serum was collected for miRNA sequencing. Serum miRNAs from young (6 month) and old (22 month) Ames dwarf (df/df) mice with GH deficiency and their WT littermates (n = 5/age/genotype group) were used for comparison. We observed 14 miRNAs regulated with a genotype by age effect and 19 miRNAs regulated with a genotype effect independent of age in serum of IGHD subjects. These regulated miRNAs are known for targeting pathways associated with longevity such as mTOR, insulin signaling, and FoxO. The aging function was overrepresented in IGHD individuals, mediated by hsa‐miR‐31, hsa‐miR‐146b, hsa‐miR‐30e, hsa‐miR‐100, hsa‐miR‐181b‐2, hsa‐miR‐195, and hsa‐miR‐181b‐1, which target the FoxO and mTOR pathways. Intriguingly, miR‐181b‐5p, miR‐361‐3p, miR‐144‐3p, and miR‐155‐5p were commonly regulated in the serum of humans and GH‐deficient mice. In vitro assays confirmed target genes for the main up‐regulated miRNAs, suggesting miRNAs regulated in IGHD individuals can regulate the expression of age‐related genes. These findings indicate that systemic miRNAs regulated in IGHD individuals target pathways involved in aging in both humans and mice.